Pharmafile Logo
Pharmafocus logo
Advanced Search

Bavencio

Showing 13 posts of 13 posts found.

bavencio_merck_large

Pfizer and Merck KGaA secure CHMP recommendation for Bavencio in Europe for first-line maintenance of urothelial carcinoma

December 14, 2020
Sales and Marketing Bavencio, CHMP, EMA, Merck, Pfizer, pharma, urothelial carcinoma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given its recommendation for …

News
img_4190-e1376666350337-web

MHRA gives OK to Bavencio for first-line maintenance of advanced bladder cancer via the Early Access to Medicines Scheme

September 3, 2020
Sales and Marketing Bavencio, MHRA, Merck, Pfizer, UK, eams, pharma

It has been revealed that Bavencio (avelumab), jointly developed by Merck KGaA and Pfizer, has been approved by the UK …

News
shutterstock_159488225

Bavencio Phase 3 head and neck cancer trial terminated

March 16, 2020
Research and Development, Sales and Marketing Bavencio, Cancer, EMD Serono, Merck KGaA, Pfizer, trial failure

Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial …

News
shutterstock_38078521

Bavencio extends survival at Phase 3 in previously untreated locally advanced or metastatic urothelial carcinoma

January 7, 2020
Manufacturing and Production, Research and Development Bavencio, Merck KGaA, Pfizer, pharma

Bavencio (avelumab), the anti-programmed death ligand-1 (PD-L1) antibody co-developed by Pfizer and Merck KGaA’s biopharma unit EMD Serono, has been …

News
bavencio

Pfizer and Merck KGaA’s Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial

November 8, 2019
Medical Communications, Research and Development Bavencio, Merck KGaA, Pfizer, pharma

Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …

News
credit_-_daniel_leal-olivas-afp

Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer

October 29, 2019
Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma

Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …

News
shutterstock_38078521

Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer

February 18, 2019
Research and Development, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma

New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …

News
shutterstock_159488225

Merck KGaA and Pfizer’s Bavencio falls short in ovarian cancer

November 20, 2018
Manufacturing and Production, Research and Development Bavencio, Cancer, Merck MGaA, Pfizer, ovarian cancer, pharma

Merck KGaA and Pfizer’s Bavencio (avelumab) has missed its primary endpoints in the treatment of platinum-resistant or -refractory ovarian cancer, …

News
11149low_reception_in_darm

Merck/Pfizer’s Bavencio wins slight reprieve after NICE nod

March 1, 2018
Medical Communications, Sales and Marketing Bavencio, Merck, Pfizer, biotech, drugs, pharma, pharmaceutical

Just two weeks ago, Merck KGaA and Pfizer were hit with a major setback for their PD-L1 immunotherapy, Bavencio, after …

News
mr058666-web

Merck KGaA and Pfizer’s Bavencio fails at Phase 3 in gastric cancer

November 28, 2017
Research and Development Bavencio, Cancer, Merck, Pfizer, pharma

Merck KGaA and Pfizer have been rocked by the news that their jointly-developed anti-PD-L1 antibody failed to meet its primary …

News

Merck and Pfizer’s joint skin cancer drug gets EU approval

September 21, 2017
Sales and Marketing Bavencio, Cancer, Merck, Pfizer, merkel cell carcinoma, pharma, pharmaceutical, skin canceer

Merck KGaA and Pfizer have announced that European authorisation of their jointly developed drug Bavencio (avelumab) as a monotherapy in …

News

Pfizer’s major drug doubles sales but overall revenue falls

August 1, 2017
Research and Development, Sales and Marketing Bavencio, Pfizer, biotech, drugs, pharma, pharmaceutical, viagra

Pfizer revealed in its briefing on its second quarter financials that Ibrance, its breast cancer treatment, had grown in sales …

News
merck_kgaa_pyramid_use_with_credit

Merck KGaA and Pfizer enter the immunotherapy market with Bavencio

March 27, 2017
Sales and Marketing Bavencio, Merck KGaA, Pfizer

Merck KGaA and Pfizer have won approval for the fourth immunotherapy treatment to enter the market, with an indication in …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023